Patient and liver tumor characteristics prior to the start of treatment
| Clinical variables | Value |
|---|---|
| Number of subjects | 48 |
| Agea [mean ± standard deviation (SD), years] | 55.3 ± 18 |
| Sex (female:male) | 25:23 |
| Number of lesions | 94 |
| KRAS positive | 29/48 (60.4%) |
| Extrahepatic disease | 23/48 (47.9%) |
| The median time between MRI and chemotherapy (days) | 23 |
| Local tumor progression | 17/48 (35.4%) |
| Chemoradiotherapy | 17/48 (35.4%) |
| Follow-up (months) | 34.9 21 |
| Location of primary tumor | |
| Ascending colon | 35/48 (72.9%) |
| Transverse colon | 2/48 (4.2%) |
| Descending and sigmoid colon | 11/48 (22.9%) |
| MSI | |
| No testing available | 30/48 (62.5%) |
| MSI-low (L) | 17/48 (35.4%) |
| MSI-high (H) | 1/48 (2.1%) |
| Tumor number | |
| 1 | 31/48 (64.6%) |
| > 1 | 17/48 (35.4%) |
| TNM classification | |
| II or III | 4/48 (8.3%) |
| IV | 44/48 (91.7%) |
| Tumor size | |
| ≤ 3 cm | 61/94 (64.9%) |
| > 3 cm | 33/94 (35.1%) |
| Chemotherapy regimen | |
| FOLFIRI | 4/48 (8.3%) |
| FOLFOX | 44/48 (91.7%) |
a at the time of MRI